

**Fermenta Biotech Limited** (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899

Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



Ref: F.No.:49

June 29, 2021

**Corporate Relations**

**BSE Limited,**

**Phiroze Jeejeebhoy Towers,**

**Dalal Street, Fort,**

**Mumbai – 400 001**

Dear Sirs,

**Sub.: Outcome of Board Meeting and Financial Results - Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

**Ref: Scrip Code: 506414**

We write to inform you that the Board of Directors of the Company at its meeting held on June 29, 2021 has, *inter alia*:

1. Approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2021 as per Regulation 33 of the Listing Regulations.

The Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2021 along with the Auditors' Reports with unmodified opinion on the aforesaid Audited Financial Results (Standalone and Consolidated) issued by the Statutory Auditors, Deloitte Haskins & Sells, LLP, Chartered Accountants, dated June 29, 2021 are enclosed herewith.

2. Recommended final equity dividend @ Rs. 2.50/- per equity share (50%) of Rs. 5 each for the financial year ended March 31, 2021 for members' approval. (Date of dispatch/payment of the aforesaid final equity dividend shall be announced separately).

The Board meeting commenced at 5.40 p.m. and concluded at 7.00 p.m.

Thanking you,

Yours faithfully,

for **Fermenta Biotech Limited**

**(Formerly known as DIL Limited)**

**Srikant N Sharma**

**Company Secretary**

CS Membership No: F3617

A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610

Encl.: as above

Factory : Village Takoli, P.O. Nagwain,  
Dist. Mandi - 175 121, Himachal Pradesh, India.

Tel. : +91-1905-287246 / 48 / 49

Fax: +91-1905-287250

Email: info@fermentabiotech.com

Website: www.fermentabiotech.com

Factory : Z - 109 B & C, SEZ II, Dahej,  
Taluka - Vagara, Dist: Bharuch - 392 130,  
Gujarat, India.

Tel. : +91-2641-291440 / 444

Email: info@fermentabiotech.com

Website: www.fermentabiotech.com



Fermenta Biotech Limited (Formerly Known as DIL Limited)

CIN:L99999MH1951PLC008485

Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.

Tel:+91-22-67980888, Fax:+91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021											(₹ in Lakhs)
Sr. No.	Particulars	Standalone					Consolidated				
		Quarter Ended			Audited Year Ended		Quarter Ended			Audited Year Ended	
		Unaudited	Unaudited	Unaudited			Unaudited	Unaudited	Unaudited		
		March 31,	December 31,	March 31,	March 31,	March 31,	March 31,	December 31,	March 31,	March 31,	March 31,
		2021	2020	2020	2021	2020	2021	2020	2020	2021	2020
	[Refer Note 11]		[Refer Note 11]			[Refer Note 11]		[Refer Note 11]			
1	Income										
	a) Revenue from operations	9,090.33	8,766.96	7,209.57	37,282.15	30,050.65	9,948.52	8,998.53	6,454.06	37,728.88	29,294.92
	b) Other income	374.35	66.08	264.54	661.81	1,231.32	463.38	68.97	263.82	825.05	1,232.30
2	Total Income (a+b)	9,464.68	8,833.04	7,474.11	37,943.96	31,281.97	10,411.90	9,067.50	6,717.88	38,553.93	30,527.22
3	Expenses										
	a) Cost of materials consumed	3,757.71	3,888.34	2,932.70	13,883.49	10,296.33	3,763.08	3,903.40	3,197.64	14,194.63	10,561.26
	b) Purchases of stock-in-trade	42.72	1.70	13.22	68.31	50.15	1,895.63	197.84	13.22	2,117.36	50.15
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	(629.12)	(1,214.05)	(444.28)	(1,587.56)	(2,078.85)	(1,088.51)	(1,227.59)	(1,074.33)	(2,874.72)	(2,708.90)
	d) Employee benefits expense	1,357.04	1,492.05	1,098.48	5,749.88	5,003.15	1,416.60	1,504.18	1,098.49	5,821.57	5,003.15
	e) Finance costs	501.93	396.26	403.61	1,807.48	1,932.04	502.41	392.76	399.12	1,797.46	1,914.04
	f) Depreciation and amortisation expense	594.23	467.25	392.67	1,903.14	1,493.83	640.56	499.69	396.25	2,030.84	1,499.97
	g) Commission on sales	68.99	50.75	30.33	758.68	908.81	75.26	53.77	30.33	767.97	908.81
	h) Other expenses	2,686.99	2,232.86	2,227.18	9,037.64	8,921.85	2,868.83	2,346.97	2,245.52	9,535.76	8,956.73
	Total expenses (a to h)	8,380.49	7,315.16	6,653.91	31,621.06	26,527.31	10,073.86	7,671.02	6,306.24	33,390.87	26,185.21
4	Profit before tax (2-3)	1,084.19	1,517.88	820.20	6,322.90	4,754.66	338.04	1,396.48	411.64	5,163.06	4,342.01
5	Tax expense (see Note 6)										
	a) Current tax	188.44	267.85	150.04	1,125.79	336.55	189.31	268.64	149.65	1,129.02	338.88
	b) Deferred tax charge/(credit)	(70.82)	144.94	(50.64)	0.26	(1,948.92)	(290.06)	144.93	(50.63)	(219.00)	(1,948.89)
	Total tax expense (a+b)	117.62	412.79	99.40	1,126.05	(1,612.37)	(100.75)	413.57	99.02	910.02	(1,610.01)
6	Profit for the period after tax but before share of profit/(loss) of an associate and non-controlling interests (4-5)	966.57	1,105.09	720.80	5,196.85	6,367.04	438.79	982.91	312.62	4,253.04	5,952.02
7	Share of profit / (loss) of an associate	-	-	-	-	-	-	-	-	-	-
8	Net Profit after tax and share of profit/(loss) of an associate and but before non-controlling interests (6+7)	966.57	1,105.09	720.80	5,196.85	6,367.04	438.79	982.91	312.62	4,253.04	5,952.02
9	Non-controlling interests						300.77	(3.16)	1.03	297.62	0.58
10	Profit for the period after tax, share of profit/(loss) of an associate and non-controlling interests (8+9)	966.57	1,105.09	720.80	5,196.85	6,367.04	739.56	979.75	313.65	4,550.66	5,952.60
11	Other Comprehensive Income										
	(A) i) Items that will not be reclassified to Profit or Loss	(6.18)	(1.03)	243.94	(5.76)	251.97	(6.18)	(1.03)	243.94	(5.76)	251.97
	ii) Income tax thereon	1.49	-	(70.07)	1.49	(70.07)	1.49	-	(70.07)	1.49	(70.07)
	(B) Items that will be reclassified to Profit or Loss	-	-	-	-	-	5.69	(19.14)	(8.33)	(22.97)	(8.33)
	Total other comprehensive income/(Loss) (A+B)	(4.69)	(1.03)	173.87	(4.27)	181.90	1.00	(20.17)	165.54	(27.24)	173.57
12	Total Comprehensive Income for the period/year (8+11)	961.88	1,104.06	894.67	5,192.58	6,548.94	439.79	962.74	478.16	4,225.80	6,125.59
	Attributable to:										
	- Owners of the parent						740.56	959.58	479.19	4,523.42	6,126.17
	- Non-controlling interests						(300.77)	3.16	(1.03)	(297.62)	(0.58)
13	Paid-up equity share capital (Face value ₹ 5/- per share) - 2,88,47,322 number of equity shares	1,442.37	1,442.37	1,442.37	1,442.37	1,442.37	1,442.37	1,442.37	1,442.37	1,442.37	1,442.37
14	Earnings per equity share of ₹ 5 each (not annualised)										
	a) ₹ Basic	3.35	3.83	2.50	18.02	22.07	2.56	3.40	1.09	15.77	20.63
	b) ₹ Diluted	3.35	3.83	2.50	17.92	21.96	2.56	3.39	1.09	15.69	20.53

See accompanying notes to the Standalone and Consolidated financial results

AMS RKB

## Notes

1 Balance Sheet as at		₹ in Lakhs			
PARTICULARS		Standalone		Consolidated	
		March 31, 2021 Audited	March 31, 2020 Audited	March 31, 2021 Audited	March 31, 2020 Audited
	<b>ASSETS</b>				
1	<b>Non-current assets</b>				
(a)	Property, plant and equipment	15,375.65	10,395.19	15,378.50	10,400.35
(b)	Capital work-in-progress	5,270.11	6,707.51	5,270.11	6,707.51
(c)	Right of use assets	1,471.82	1,615.70	1,292.55	1,428.46
(d)	Investment property	6,820.29	7,075.00	6,870.38	7,126.17
(e)	Goodwill	411.65	411.65	1,071.35	412.79
(f)	Other Intangible assets	877.44	184.06	1,680.35	647.56
(g)	Intangible assets under development	420.55	369.38	420.55	369.38
(h)	Investments				
i)	Investments in subsidiaries	1,270.02	85.30	-	-
ii)	Investments in an associate	-	-	-	-
(i)	Financial assets				
i)	Investments	24.94	25.60	24.94	25.60
ii)	Share application money	-	-	-	-
iii)	Loans	1.85	25.00	1.85	25.00
iv)	Others financial assets	219.25	405.68	219.25	405.68
(j)	Deferred tax assets (net)	3,811.18	3,809.95	4,031.01	3,810.51
(k)	Non-current tax assets (net)	1,129.52	906.59	1,131.38	908.25
(l)	Other non-current assets	353.25	698.88	353.25	698.88
	Sub-total - Non-current assets	37,457.52	32,715.49	37,745.47	32,966.14
2	<b>Current assets</b>				
(a)	Inventories	13,279.27	11,354.43	16,227.05	12,858.19
(b)	Financial assets				
i)	Trade receivables	9,611.96	7,744.28	6,801.48	6,977.42
ii)	Cash and cash equivalents	1,356.57	677.41	1,679.44	751.45
iii)	Bank balances other than (ii) above	2,773.80	2,559.54	2,773.80	2,559.54
iv)	Loans	476.60	2,130.00	476.60	2,130.00
v)	Other financial assets	795.01	1,294.12	347.83	637.27
(c)	Other current assets	2,503.05	2,485.79	2,655.95	2,487.44
	Sub-total - Current assets	30,796.26	28,245.57	30,962.15	28,401.31
	<b>TOTAL ASSETS</b>	<b>68,253.78</b>	<b>60,961.06</b>	<b>68,707.62</b>	<b>61,367.45</b>
	<b>EQUITY AND LIABILITIES</b>				
1	<b>EQUITY</b>				
(a)	Equity Share capital	1,442.37	1,442.37	1,442.37	1,442.37
(b)	Other Equity	35,602.45	29,817.82	34,616.65	29,501.17
	Equity attributable to the owners of the Company	37,044.82	31,260.19	36,059.02	30,943.54
(c)	Non-controlling interests	-	-	(29.63)	1.24
	Total Equity	37,044.82	31,260.19	36,029.39	30,944.78
2	<b>Non-current liabilities</b>				
(a)	Financial liabilities				
i)	Borrowings	11,043.80	10,178.67	11,043.80	10,178.67
ii)	Lease liabilities	349.01	450.96	170.02	264.07
iii)	Other financial liabilities	47.82	59.44	47.82	59.44
(b)	Provisions	449.20	405.83	449.20	405.83
(c)	Other non-current liabilities	34.04	54.93	34.04	54.93
	Sub-total - Non-current liabilities	11,923.87	11,149.83	11,744.88	10,962.94
3	<b>Current liabilities</b>				
(a)	Financial Liabilities				
i)	Borrowings	9,629.95	10,433.30	9,629.95	10,433.30
ii)	Lease liabilities	116.46	105.19	116.19	104.85
iii)	Trade payables				
	-Total outstanding dues of micro and small enterprises and;	78.34	98.01	78.34	98.01
	-Total outstanding dues of creditors other than micro enterprises and small enterprises	4,491.51	4,619.37	6,135.37	5,535.46
iv)	Other financial liabilities	4,103.35	2,973.78	4,103.34	2,973.76
(b)	Provisions	74.87	55.76	770.33	48.71
(c)	Other current liabilities	758.60	233.61	67.82	233.62
(d)	Current tax liabilities (Net)	32.01	32.02	32.01	32.02
	Sub-total - Current liabilities	19,285.09	18,551.04	20,933.35	19,459.73
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>68,253.78</b>	<b>60,961.06</b>	<b>68,707.62</b>	<b>61,367.45</b>

ANS  
RKG

## NOTES:

2A Segment Information		(₹. in Lakhs)				
Particulars	Standalone					
	Quarter ended			Year Ended		
	Unaudited	Unaudited	Unaudited	Audited	Audited	
	March 31,	December 31,	March 31,	March 31,	March 31,	
	2021	2020	2020	2021	2020	
[Refer Note 11]		[Refer Note 11]				
Segment revenue						
- Bulk drugs/chemicals	8,655.51	8,336.23	6,754.11	35,537.24	28,305.62	
- Property	434.82	430.72	443.16	1,744.91	1,945.05	
- Unallocated	374.35	66.09	276.84	661.81	1,313.66	
Total	9,464.68	8,833.04	7,474.11	37,943.96	31,564.33	
Less : Inter-segment revenue	-	-	-	-	282.36	
Total Income	9,464.68	8,833.04	7,474.11	37,943.96	31,281.97	
Segment results						
- Bulk drugs/chemicals	983.60	1,752.11	1,117.13	7,028.44	5,958.00	
- Property	208.35	240.17	119.99	924.48	571.30	
- Unallocated (Net)	394.17	(78.14)	(13.31)	177.46	157.40	
Total	1,586.12	1,914.14	1,223.81	8,130.38	6,686.70	
Less: Inter-segment results	-	-	-	-	-	
Total Profit before tax and before finance cost	1,586.12	1,914.14	1,223.81	8,130.38	6,686.70	
Less : Finance costs	(501.93)	(396.26)	(403.61)	(1,807.48)	(1,932.04)	
Total Profit before tax	1,084.19	1,517.88	820.20	6,322.90	4,754.66	
Segment Assets						
- Bulk Drugs/chemicals	48,292.31	44,260.05	40,418.44	48,292.31	40,418.44	
- Property	7,496.72	7,612.35	8,014.40	7,496.72	8,014.40	
- Unallocated	12,464.75	12,751.89	12,528.22	12,464.75	12,528.22	
Total Segment Assets	68,253.78	64,624.29	60,961.06	68,253.78	60,961.06	
Segment Liabilities						
- Bulk Drugs/chemicals	6,824.54	7,458.53	6,278.80	6,824.54	6,278.80	
- Property	802.95	802.98	813.85	802.95	813.85	
- Unallocated	23,581.47	24,428.51	22,608.22	23,581.47	22,608.22	
Total Segment Liabilities	31,208.96	32,690.02	29,700.87	31,208.96	29,700.87	

2B Segment Information		(₹. in Lakhs)				
Particulars	Consolidated					
	Quarter ended			Year Ended		
	Unaudited	Unaudited	Unaudited	Audited	Audited	
	March 31,	December 31,	March 31,	March 31,	March 31,	
	2021	2020	2020	2021	2020	
[Refer Note 11]		[Refer Note 11]				
Segment revenue						
- Bulk drugs/chemicals	9,439.88	8,570.70	5,999.32	35,983.97	27,550.83	
- Property	439.32	435.22	447.61	1,762.91	1,963.05	
- Unallocated	537.20	66.08	275.19	825.05	1,313.70	
Total	10,416.40	9,072.00	6,722.12	38,571.93	30,827.58	
Less : Inter-segment revenue	4.50	4.50	4.24	18.00	300.36	
Total Income	10,411.90	9,067.50	6,717.88	38,553.93	30,527.22	
Segment results						
- Bulk drugs/chemicals	234.38	1,627.90	692.96	5,857.16	5,533.83	
- Property	211.52	239.06	128.12	924.24	563.10	
- Unallocated (Net)	394.12	(78.14)	(13.30)	177.41	157.41	
Total	840.02	1,788.82	807.78	6,958.81	6,254.34	
Less: Inter-segment results	0.43	0.42	2.98	1.71	1.71	
Total Profit before tax and before finance cost	840.45	1,789.24	810.76	6,960.52	6,256.05	
Less : Finance costs	(502.41)	(392.76)	(399.12)	(1,797.46)	(1,914.04)	
Total Profit before tax	338.04	1,396.48	411.64	5,163.06	4,342.01	
Segment Assets						
- Bulk Drugs/chemicals	48,505.21	49,039.82	40,580.16	48,505.21	40,580.16	
- Property	7,548.25	7,666.77	8,069.03	7,548.25	8,069.03	
- Unallocated	12,654.16	12,940.95	12,718.26	12,654.16	12,718.26	
Total Segment Assets	68,707.62	69,647.54	61,367.46	68,707.62	61,367.45	
Segment Liabilities						
- Bulk Drugs/chemicals	8,570.50	9,376.52	7,289.02	8,570.50	7,289.02	
- Property	803.18	813.56	814.09	803.18	814.09	
- Unallocated	23,304.55	24,136.13	22,319.56	23,304.55	22,319.56	
Total Segment Liabilities	32,678.23	34,326.21	30,422.67	32,678.23	30,422.67	

RKG

ANS

D

3 Statement of Cash Flows		(₹ in Lakhs)			
		Standalone		Consolidated	
Particulars	Year Ended		Year Ended		
	Audited	Audited	Audited	Audited	
	March 31,	March 31,	March 31,	March 31,	
	2021	2020	2021	2020	
<b>A) CASH FLOWS FROM OPERATING ACTIVITIES</b>					
Profit before tax	6,322.90	4,754.66	5,163.06	4,342.01	
<b>Adjustments for:</b>					
Depreciation and amortisation expense	1,903.14	1,493.83	2,030.84	1,499.97	
Net unrealised foreign exchange (gain)/loss	(206.32)	81.72	(226.06)	73.40	
Loss on sale/write off of property, plant and equipment (Net)	16.03	15.53	16.03	15.53	
Allowance for doubtful debts	118.96	91.46	118.96	91.46	
Share based payments to employees	592.05	554.69	592.05	554.69	
Finance costs	1,807.48	1,932.04	1,797.46	1,914.04	
Interest income	(354.61)	(564.53)	(354.61)	(564.53)	
Dividend income	(0.58)	(0.44)	(0.58)	(0.44)	
Liabilities / provisions no longer required written back	(54.21)	(296.59)	(214.20)	(296.59)	
Trade receivables and advances written off	90.96	42.33	90.96	42.33	
Allowance for doubtful advances	-	31.96	-	31.96	
Impairment in the value of non-current investments	-	47.53	-	43.94	
Gain on sale of financial assets - current investments	-	(4.81)	-	(4.81)	
Net loss on fair value changes of derivatives measured at FVTPL	110.15	-	110.15	-	
<b>Operating Profit before working capital changes</b>	<b>10,345.95</b>	<b>8,179.38</b>	<b>9,124.06</b>	<b>7,742.96</b>	
<b>Movements in working capital:</b>					
(Increase)/decrease in trade receivables	(1,561.90)	(751.38)	646.07	9.70	
Increase in inventories	(1,924.84)	(2,587.90)	(1,916.60)	(4,091.66)	
(Increase)/decrease in other assets	127.50	476.01	(215.25)	1,131.50	
Increase/(decrease) in trade payables	(59.27)	566.21	(752.50)	1,554.66	
Increase in provisions	57.37	14.01	57.37	14.00	
Increase/(decrease) in other liabilities	659.67	(1,521.63)	668.73	(1,520.76)	
	<b>7,644.48</b>	<b>4,374.70</b>	<b>7,611.88</b>	<b>4,840.40</b>	
Income taxes paid (net of refunds)	(1,348.73)	(1,391.41)	(1,352.16)	(1,394.44)	
<b>Net cash generated from operations (A)</b>	<b>6,295.75</b>	<b>2,983.29</b>	<b>6,259.72</b>	<b>3,445.96</b>	
<b>B) CASH FLOWS FROM INVESTING ACTIVITIES</b>					
Payments for purchase of property, plant and equipment, investment property, capital work-in-progress, intangible assets and intangible assets under development	(5,491.96)	(6,380.75)	(5,527.09)	(6,846.93)	
Proceeds on sale of property, plant and equipment	1.32	-	1.27	-	
Intercompany deposits given	-	(980.00)	-	(980.00)	
Intercompany deposits received back	1,655.00	-	1,655.00	-	
Interest received	478.80	460.09	478.81	460.09	
Acquisition of a subsidiary	-	-	(943.85)	-	
Proceeds from share application money received back	-	597.00	-	597.00	
Proceeds from sale of current investments	-	119.60	-	119.60	
Purchase of investments - In a subsidiary	(1,184.72)	(19.33)	-	-	
Dividend received	0.58	0.44	0.58	0.44	
Deposits (placed with)/ received back from a financial institution	400.00	(300.00)	400.00	(300.00)	
Deposits with Banks not considered as cash and cash equivalents (net)	(219.70)	2,583.88	(219.70)	2,583.88	
<b>Net cash used in investing activities (B)</b>	<b>(4,360.68)</b>	<b>(3,919.07)</b>	<b>(4,154.98)</b>	<b>(4,365.92)</b>	
<b>C) CASH FLOWS FROM FINANCING ACTIVITIES</b>					
Proceeds from long term borrowings	2,916.54	3,085.98	2,916.54	3,085.98	
Repayment of long term borrowings	(1,500.49)	(6,528.31)	(1,500.50)	(6,528.31)	
Net increase in short term borrowings	358.46	1,688.96	358.46	1,688.96	
Finance costs	(1,753.43)	(2,055.93)	(1,753.42)	(2,055.93)	
Repayment of Lease Liabilities	(153.41)	(231.85)	(135.40)	(213.86)	
Dividends paid	-	(597.16)	-	(597.16)	
Dividend distribution tax paid	-	(124.42)	-	(124.42)	
<b>Net cash used in financing activities (C)</b>	<b>(132.33)</b>	<b>(4,762.73)</b>	<b>(114.32)</b>	<b>(4,744.74)</b>	
<b>Net increase/(decrease) in cash and cash equivalents (A)+(B)+(C)</b>	<b>1,802.74</b>	<b>(5,698.51)</b>	<b>1,990.42</b>	<b>(5,664.70)</b>	
Cash and cash equivalents taken over on acquisition of a subsidiary	-	-	61.15	-	
Cash and cash equivalents at the beginning of the year	(1,896.48)	3,802.03	(1,822.44)	3,842.26	
Cash and cash equivalents at the end of the year	(93.74)	(1,896.48)	229.13	(1,822.44)	
<b>Components of cash and cash equivalents</b>					
Cash on hand	4.77	4.31	4.77	4.32	
Balances with banks					
In current accounts	1,022.65	673.10	1,345.52	747.13	
In deposit accounts with original maturity for less than 3 months	329.15	-	329.15	-	
Cash and cash equivalents	<b>1,356.57</b>	<b>677.41</b>	<b>1,679.44</b>	<b>751.45</b>	
Bank overdraft/Cash credit facilities	(1,450.31)	(2,573.89)	(1,450.31)	(2,573.89)	
<b>Total cash and cash equivalents considered for cash flows</b>	<b>(93.74)</b>	<b>(1,896.48)</b>	<b>229.13</b>	<b>(1,822.44)</b>	

AMS RKG

- 4 The financial results included in the above statement of standalone and consolidated results includes the financial information of two subsidiaries and one associate on the basis of unaudited financial information prepared by the Management which have been not reviewed or audited by their auditors. The said interim financial information is not material to the consolidated results.
- 5 These standalone and consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 6 The National Company Law Tribunal, Mumbai Bench, has approved the Scheme of Amalgamation between DIL Limited and Fermenta Biotech Limited and their respective shareholders, and the name of DIL Limited has been changed to Fermenta Biotech Limited. The Scheme has become effective from 26th September, 2019. The appointed date of the Scheme is 1st April, 2018. The amalgamation had been accounted as common control transaction in accordance with Appendix C of Ind AS 103 'Business Combinations'.
- 7 As per the current assessment of the situation based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Company believes that the Impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited. The eventual outcome of the impact of the global health pandemic may be different from those-estimated as on the date of approval of these standalone financial results and consolidated financial results and the Company will closely monitor any material changes to the economic environment and their impact on its business in the times to come.
- 8 The Company had given (unsecured) Inter-corporate deposits aggregating ₹ 2,130.00 Lakhs in various tranches to another entity for the development of the new product i.e. cholesterol from Fish Oil. The amount outstanding as on 31st March, 2021 is ₹ 521.96 Lakhs, including interest of ₹ 46.96 Lakhs. Subsequent to the end of the quarter, the other entity has further repaid an amount of ₹ 521.96 Lakhs towards the aggregate outstanding as mentioned above, and there is no outstanding against the said Inter-corporate deposits as on date.

In view of the changed position as above, this matter no longer remains a subject matter of qualification in the report on the Company's standalone and consolidated financial results for the quarter and year ended 31st March, 2021.

- 9 On 1st December, 2020, Fermenta Biotech USA, LLC, a wholly owned subsidiary of the Company, has acquired 52% of membership interest in AGD Nutrition, LLC which is in to similar line of business of the Company. The Company has determined the fair values as at the acquisition date based on valuation report obtained from an independent valuer and completed the accounting as stipulated by the Ind AS 103-'Business Combinations' in the consolidated financial results for the quarter and year ended 31st March, 2021. The name of AGD Nutrition LLC has since been changed to Fermenta USA LLC.
- 10 The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in these financial results when the Rules/Schemes thereunder are notified.
- 11 The figures for the quarter ended 31st March, 2021 and 31st March, 2020 are the balancing figures between the audited figures in respect of the full financial year ended 31st March, 2021 and 31st March, 2020 and the unaudited published year to date figures upto the nine months ended 31st December, 2020 and 31st December, 2019 of the relevant financial year which were subject to limited review by the statutory auditors.
- 12 The Board of Directors at their meeting held on 29th June, 21 have proposed a dividend of 50% ( ₹ 2.50 per share) for the financial year ended 2020-2021. The payment of dividend is subject to approval of shareholders in the ensuing Annual General Meeting.
- 13 The above standalone and consolidated financial results of the Company for the quarter and year ended 31st March, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29th June, 2021.

Place: Thane  
29th June, 2021

RKG AMS

Prashant Nagre  
Managing Director

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF**

**Fermenta Biotech Limited (Formerly known as DIL Limited)**

**Opinion and Conclusion**

We have (a) audited the Standalone Financial Results and the Consolidated Financial Results for the year ended March 31, 2021 and (b) reviewed the Standalone Financial Results and the Consolidated Financial Results for the quarter ended March 31, 2021 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone and Consolidated Financial Results for the Quarter and Year Ended March 31, 2021" of Fermenta Biotech Limited (Formerly known as DIL Limited) ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income/ loss of its associate for the quarter and year ended March 31, 2021, ("the Statement"), being submitted by the Parent, pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Standalone Financial Results and Consolidated Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of the subsidiaries referred to in Other Matters section below, the Statement for the year ended March 31, 2021:

i. includes the results of the following entities in the Consolidated Financial Results, included in the Statement:

<b>Parent</b>
1. Fermenta Biotech Limited (Formerly known as DIL Limited)
<b>Subsidiaries</b>
2. Aegean Properties Limited
3. CC Square Films Limited
4. G. I. Biotech Private Limited
5. Fermenta Biotech (UK) Limited
6. Fermenta Biotech GmbH
7. Fermenta Biotech USA LLC
8. Fermenta USA LLC
<b>Associate</b>
9. Health and Wellness India Private Limited

ii. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and

iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, respectively, of the net standalone profit/ consolidated profit, total standalone comprehensive income/ total consolidated comprehensive income and other financial information of the Parent and the Group for the year ended March 31, 2021.

*RKB AMS*

**(b) Conclusion on Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended March 31, 2021**

With respect to the Standalone Financial Results and Consolidated Financial Results for the quarter ended March 31, 2021, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results and Consolidated Financial Results for the quarter ended March 31, 2021, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Basis for Opinion on the Audited Standalone Financial Results and Consolidated Financial Results for the year ended March 31, 2021 and**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group and its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results and Consolidated Financial Results for the year ended March 31, 2021 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

**Management's Responsibilities for the Statement**

This Statement, which includes the Standalone Financial Results and Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for issuance. The Standalone Financial Results and Consolidated Financial Results for the year ended March 31, 2021, have been compiled from the related audited standalone financial statements and audited consolidated financial statements, respectively. This responsibility includes the preparation and presentation of the Standalone Financial Results and Consolidated Financial Results for the quarter and year ended March 31, 2021 that give a true and fair view of the net standalone profit/ consolidated profit, standalone other comprehensive income/ consolidated other comprehensive income and other financial information of the Parent, and the Group including its associate in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of these Standalone Financial Results and Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Standalone Financial Results and Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

# Deloitte Haskins & Sells LLP

The respective Board of Directors of the companies included in the Group and of its associate are responsible for overseeing the financial reporting process of the Group and of its associate.

## Auditor's Responsibilities

### (a) Audit of the Standalone Financial Results and Consolidated Financial Results for the year ended March 31, 2021

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results and Consolidated Financial Results for the year ended March 31, 2021, as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results and Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results and Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Results and Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results and Annual Consolidated Financial Results, including the disclosures, and whether the Annual Standalone Financial Results and Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results/ Financial information of the entities within the Group and its associate to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entity included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

AMS

RKH

# Deloitte Haskins & Sells LLP

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results and Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results and Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results and Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent included in the Standalone Financial Results and Consolidated Financial Results where we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## **(b) Review of the Standalone Financial Results and Consolidated Financial Results for the quarter ended March 31, 2021**

We conducted our review of the Standalone Financial Results and Consolidated Financial Results for the quarter ended March 31, 2021, respectively, in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Consolidated Financial Results, included in the Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

## **Other Matters**

- The Statement includes the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.
- We did not audit the financial statements of 5 subsidiaries, included in the Consolidated Financial Results, included in the Statement, whose financial statements reflect total assets of Rs. 6,430.89 Lakhs as at March 31, 2021 and total revenues of Rs. 2,012.68 Lakhs and Rs. 2,805.49 Lakhs for the quarter and year ended March 31, 2021 respectively, total net loss after tax of Rs. 624.70 Lakhs and Rs. 796.78 Lakhs for the quarter and year ended March 31, 2021 respectively, and total comprehensive loss (net) of Rs. 624.70 Lakhs and Rs. 796.78 Lakhs for the quarter and year ended March 31, 2021 respectively, as considered in the Consolidated Financial Results, included in the Statement. The above figures are before giving effect of any consolidation adjustments. These financial statements have been audited/reviewed, as applicable, by other auditors whose reports have been furnished to us by the Management of the Parent and our opinion and conclusion on the Consolidated Financial Results, included in the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Consolidated Financial Results, included in the Statement, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

AMS

RKG

# Deloitte Haskins & Sells LLP

- The Consolidated Financial Results includes the unaudited financial information of 2 subsidiaries, whose financial information reflect total assets of Rs. 40.70 Lakhs as at March 31, 2021 and total revenues of Rs. 0.31 Lakhs and Rs. 2.85 Lakhs for the quarter and year ended March 31, 2021 respectively, total net loss after tax of Rs. 0.87 Lakhs and total net profit after tax of Rs. 1.63 Lakhs for the quarter and year ended March 31, 2021 respectively, and total comprehensive loss of Rs. 0.87 Lakhs and total comprehensive profit of Rs. 1.63 Lakhs for the quarter and year ended March 31, 2021 respectively and net cash inflows of Rs. 3.02 Lakhs for the year ended March 31, 2021, as considered in the Consolidated Financial Results, included in the Statement. The Consolidated Financial Results also includes the Group's share of profit/(loss) after tax of Rs. Nil and total comprehensive income of Rs. Nil, both, for the quarter and year ended March 31, 2021, respectively, as considered in the Consolidated Financial Results, included in the Statement, in respect of an associate, whose financial information have not been audited by us. The above figures are before giving effect of any consolidation adjustments. These financial information are unaudited and have been furnished to us by the Management of the Parent and our opinion and conclusion on the Consolidated Financial Results, included in the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Parent's Board of Directors, these financial information are not material to the Group.

Our report on the Consolidated Financial Results, included in the Statement, is not modified in respect of the above matter with respect to our reliance on the financial information certified by the Parent's Board of the Directors.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
Partner  
(Membership No. 36920)  
UDIN: 21036920AAAACQ6227

AMS  
RKH

Place: Mumbai

Date: June 29, 2021